Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to see if it is safe and effective to add a new protease inhibitor (PI), 141W94, to an anti-HIV regimen that includes 2 nucleoside reverse transcriptase inhibitors (NRTIs).
Condition or disease
In this double-blind, placebo-controlled, pediatric study, 210 patients are randomized to receive 2 NRTIs plus either 141W94 or placebo. Enrollment of patients is sequential: patients 13 to 18 years of age are enrolled first, followed by children < 13 when the appropriate pediatric dose has been determined. Patients who are unable to swallow capsules will be accrued when a liquid formulation becomes available.
A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Safety and Efficacy of 141W94 Plus Current Nucleoside Therapy Versus Current Nucleoside Therapy Alone in Protease-Naive, HIV-Infected Children
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
6 Months to 18 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Your child may be eligible for this study if he/she:
Is 6 months - 18 years of age.
Has a viral load (level of HIV in the body) greater than 10,000 copies/ml.
Is able to take medications by mouth.
Has consent of parent or legal guardian if under 18.
Has a negative pregnancy test within 7 days of study entry.
Agrees to practice abstinence or use effective methods of birth control for 1 month before and throughout the study.
Your child will not be eligible for this study if he/she:
Has a serious illness, including any life-threatening infection or other chronic serious medical condition.
Has an opportunistic (AIDS-related) infection or a serious bacterial infection.
Is allergic to NRTIs.
Is unlikely to complete the study.
Has received certain medications.
Has received radiation therapy within the past 4 months, or will need to receive it during the study.